{"id":"ibrutinib-combined-with-as2o3","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Arsenic-related hepatotoxicity"},{"rate":null,"effect":"QT prolongation"}]},"_chembl":{"chemblId":"CHEMBL1873475","moleculeType":"Small molecule","molecularWeight":"440.51"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ibrutinib is a BTK inhibitor that disrupts B-cell receptor signaling, preventing malignant B-cell survival and proliferation. Arsenic trioxide acts as a dual-mechanism agent that promotes apoptosis and differentiation of leukemic blasts, particularly in acute promyelocytic leukemia. The combination leverages complementary mechanisms to enhance anti-leukemic activity.","oneSentence":"Ibrutinib inhibits Bruton's tyrosine kinase (BTK) to block B-cell proliferation, while arsenic trioxide (As2O3) induces apoptosis and differentiation in leukemic cells through multiple pathways.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:15:20.649Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute leukemia (investigational combination therapy)"},{"name":"B-cell malignancies with arsenic sensitization"}]},"trialDetails":[{"nctId":"NCT02757040","phase":"PHASE3","title":"Combination of Ibrutinib and As2O3 in the Treatment of CLL","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2016-12","conditions":"Leukemia, Lymphocytic, Chronic, B-Cell","enrollment":70}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ibrutinib combined with arsenic trioxide"],"phase":"phase_3","status":"active","brandName":"Ibrutinib combined with As2O3","genericName":"Ibrutinib combined with As2O3","companyName":"Peking University People's Hospital","companyId":"peking-university-people-s-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ibrutinib inhibits Bruton's tyrosine kinase (BTK) to block B-cell proliferation, while arsenic trioxide (As2O3) induces apoptosis and differentiation in leukemic cells through multiple pathways. Used for Acute leukemia (investigational combination therapy), B-cell malignancies with arsenic sensitization.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}